An errant press release from one of its development partners has triggered a 21 per cent increase in the share price of Omega Diagnostics.

In response, the Scottish diagnostics firm said yesterday afternoon: “Omega…notes the statement made by BBI Solutions Limited earlier today regarding an order from the UK Government and successful independent evaluation in relation to the AbC-19 test developed by the UK-RTC. This was released by BBI in error and contained incorrect information. The statement has been withdrawn by BBI and should be disregarded.”

READ MORE: Full launch this month as Omega gets Covid test approval

Both companies are part of the UK-RTC working to develop kits for rapid Covid-19 testing. Earlier yesterday, Omega confirmed the successful conclusion of usability tests for AbC-19 for home self-testing, though final approval is still pending. Omega shares closed 11p higher yesterday at 64.5p.